AI summary by TwinMind

3 reasons why medications are so expensive in the US - Kiah Williams

TED-Ed

5m 20s

Historical Context & Production Costs

  • Frederick Banting transferred insulin patent to University of Toronto for $1 (1921)
    • Stated "insulin belonged to the world—not to him"
  • Current production costs: <$6 per vial
  • US patients pay thousands annually—10x more than other countries
  • Some patients reduce prescribed doses due to cost

Research & Development Phase

  • R&D costs vary widely by drug
  • Failed drug development costs factored into pricing
  • Almost every approved drug subsidized by taxes
  • Pharmaceutical companies set prices without required justification

Patent Protection & Market Manipulation

  • Companies receive patent protection + exclusivity rights
  • Patent expiration typically causes price drops
  • Companies invest heavily in patent extensions
    • Make minor tweaks (dosage, delivery methods)
    • Obtain new patents, sue competitors to delay releases
  • Humira case study:
    • Best-selling autoimmune drug
    • Price raised 27x since 2003
    • Costs >$96,000/year without insurance
  • Insulin market dominated by 3 companies using similar tactics
    • Average list prices tripled over 2 decades

Distribution Channels

Retail Channel (most drugs including insulin)

  • Pharmaceutical company → wholesalers → pharmacies → patients

Hospital/Clinic Channel

  • More expensive, research-intensive therapies for rare conditions

US Healthcare Payment System

  • No universal healthcare
  • Many Americans use health insurance
  • Insured patients: pay portion, pharmacy bills insurer for rest
  • Uninsured patients: pay full non-negotiated rates

Pharmacy Benefit Managers (PBMs)

  • Companies unique to US market
  • Negotiate discounts from manufacturers for insurers
  • May pass some discounts to insurers but keep considerable portion
  • Limit patient choice
  • Sometimes cover expensive branded drugs over cheaper generics for higher profit

Financial Flow Analysis (2018 Insulin Data)

  • Manufacturers: 46%
  • Wholesalers: 8%
  • Pharmacies: 20%
  • Insurance companies: 10%
  • PBMs: 14%
  • 2014-2018 trend: as list prices increased, manufacturer retention decreased
    • >50% went to intermediaries

International Comparison

  • US: businesses negotiate at various steps
  • Other countries: government agencies evaluate benefits, bulk purchase, regulate pricing
  • US leads in drug development and profit
  • 1 in 4 Americans reported prescription affordability trouble (2019)

Reform Proposals

  • Increased regulation in drug pricing, patenting, intermediary profits
  • More national health and research funding
  • Goal: lower prices while encouraging innovation
  • Maintain pharmaceutical company profits through affordability/volume

Recent Developments (2023)

  • Largest insulin manufacturer announced substantial list price decrease
  • Two other manufacturers followed suit
  • Should improve insulin affordability
  • System-wide changes needed for comprehensive patient access

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome